{'fraction_non_alphanumeric': 0.028481012658227847, 'fraction_numerical': 0.007911392405063292, 'mean_word_length': 5.880434782608695, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
PNL2: an adjunctive biomarker for renal angiomyolipomas and perivascular epithelioid cell tumours

Renal angiomyolipoma (AML) and perivascular epithelioid cell tumour (PEComa) are members of the microphthalmia‐associated transcription factor (MiTF) family of tumours. Traditionally, HMB45 and melan‐A have been used to diagnose these lesions; however, low sensitivity can make interpretation difficult. PNL2 is a sensitive and specific biomarker for epithelioid melanoma, and immunoreactivity has also been shown in small series of PEComas. This study was aimed at determining the utility of PNL2 in MiTF and non‐MiTF renal tumours.